Dermatomyositis Drug Market, by Drug Type (Corticosteroids, Immunosuppressive Agents, and Others), by Route of Administration (Oral, Topical, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5333

Pages :166

Formats :

Excel and PDF

Industry : Pharmaceutical

Dermatomyositis Drug MarketSize and Trends

The Global dermatomyositis drug market is estimated to be valued at US$ 773.7 million in 2022 and is expected to exhibit a CAGR of 4.3% during the forecast period (2022-2030).

Figure 1.Global Dermatomyositis Drug Market Share (%) in Terms of Value, By Drug Type, 2022

Increasing prevalence of dermatomyositis is expected to drive the market growth during the forecast period

The Increasing prevalence of dermatomyositis is expected to drive the global dermatomyositis drug market growth over the forecast period. For instance, according to data published by Journal of Managed Care & Specialty Pharmacy in November 2020, estimated that the prevalence of Dermatomyositis is 2.0-10.0 cases per 100,000 persons, globally, in 2020. Moreover, the annual incidence rate of Dermatomyositis is 4.0-7.7 per 1 million persons, globally, in 2020.

Figure 2.Global Dermatomyositis Drug Market Share (%), By Distribution Channel, 2022

Increasing product approval for the treatment of dermatomyositis are expected to drive the market growth during the forecast period

Increasing product approval for the treatment of dermatomyositis is expected to drive the global dermatomyositis drug market growth during the forecast period. For instance, in August 2021, The U.S. Food and Drug Administration (FDA) had granted approval to Octapharma USA, one of the largest human protein product manufacturers for Octagam 10%, the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis.